Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)
Sponsor: Children's Hospital of Philadelphia
A PHASE1 clinical study on Lymphoblastic Leukemia, Acute, Childhood, this trial is completed. The trial is conducted by Children's Hospital of Philadelphia and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
Phase: NA → PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting NA
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Dec 2019 — Oct 2020 [monthly]
Active Not Recruiting NA
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital of Philadelphia
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .